Compounds > benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-
Page last updated: 2024-08-02 08:35:50

benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-

Description

Cross-References

ID SourceID
PubMed CID9818903
CHEMBL ID351231
SCHEMBL ID118976
MeSH IDM0480813

Synonyms (34)

Synonym
abt 239
gtpl1218
4-[2-[2-[(2r)-2-methylpyrrolidin-1-yl]ethyl]-1-benzofuran-5-yl]benzonitrile
abt239
abt-239
(r)-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)benzofuran-5-yl)benzonitrile
4-{2-[2-((r)-2-methyl-pyrrolidin-1-yl)-ethyl]-benzofuran-5-yl}-benzonitrile
bdbm50139391
CHEMBL351231 ,
460746-46-7
benzonitrile, 4-[2-[2-[(2r)-2-methyl-1-pyrrolidinyl]ethyl]-5-benzofuranyl]-
unii-86h6b395pi
(r)-4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile
86h6b395pi ,
benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-
4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile
AKOS015891396
(r)-4-(2-(2-(2-methylpyrrolidinyl)ethyl)benzofuran-5-yl)benzonitrile
SCHEMBL118976
4-(2-{2-[(2r)-2-methylpyrrolidinyl]ethyl}-1-benzofuran-5-yl)benzonitrile
4-(2-{2-[(2r)-2-methyl-1-pyrrolidinyl]ethyl}-1-benzofuran-5-yl)benzonitrile
KFHYZKCRXNRKRC-MRXNPFEDSA-N
HY-12195
DTXSID00196710
CS-5904
NCGC00386570-01
4-(2-{2-[(2r)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile
Q4650421
Z1816526082
abt-239 (tartrate)
D94991
4-(2-{2-[(2r)-2-methylpyrrolidin-1-yl]ethyl}-
benzofuran-5-yl)benzonitrile
AS-76470

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency13.4504AID1645840

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC501.6000AID616657
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki0.4000AID483431
Histamine H3 receptorRattus norvegicus (Norway rat)Ki0.0040AID239562; AID239987; AID254439; AID302561; AID302564; AID305749; AID421583; AID483430; AID611518; AID622486; AID692493; AID89566; AID89863
Histamine H3 receptorHomo sapiens (human)IC500.0006AID389212
Histamine H3 receptorHomo sapiens (human)Ki0.0017AID239591; AID239988; AID254441; AID290795; AID302560; AID305748; AID341508; AID375418; AID421582; AID483429; AID599203; AID611517; AID616658; AID622483; AID692494; AID86462; AID86612

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Histamine H3 receptorRattus norvegicus (Norway rat)EC500.0174AID302566
Histamine H3 receptorHomo sapiens (human)EC500.0013AID302565
Histamine H3 receptorHomo sapiens (human)Kd0.0129AID599205

Other Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Histamine H3 receptorHomo sapiens (human)Kb0.0072AID302562; AID302563

Bioassays (117)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID616659Lipophilicity, log D of the compound2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
ISSN: 1464-3405		Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
AID302569Clearance in rat at 1 mg/kg, iv2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302562Antagonist activity at human histamine H3 receptor expressed with Galphaq/i5 in HEL239 cells assessed as reduction of RAMH-induced intracellular calcium2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID290795Binding affinity to human histamine H3 receptor2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
ISSN: 0960-894X		A new class of histamine H3 receptor antagonists derived from ligand based design.
AID616658Displacement of [125I]Iodoproxyfan from human recombinant histamine H3 receptor by Competitive binding assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
ISSN: 1464-3405		Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
AID253633Area under plasma concentration curve of the compound upon p.o. dose of 1 mg/kg in rats2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID302575Protein binding in dog plasma2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID622483Displacement of [3H]-NAMH from human histamine H3 receptor expressed in CHO cells2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
ISSN: 1464-3405		Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
AID483431Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
ISSN: 1464-3405		In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID236518Clearance was observed in monkey after intravenous administration of 1-5 mg/kg2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID389212Antagonist activity at human cloned histamine H3 receptor expressed in CHO-K1 cells assessed as inhibition of R-alpha-methylhistamine-induced [35S]GTPgammaS binding2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
ISSN: 1520-4804		Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.
AID237276Half life was observed in monkey after intravenous administration of 3-5 mg/kg; (n=3)2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID622486Displacement of [3H]-NAMH from rat histamine H3 receptor expressed in CHO cells2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
ISSN: 1464-3405		Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
AID341508Displacement of [3H]RAMH from human histamine H3 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15
ISSN: 1464-3405		Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists.
AID237264Half life was observed in rat after intravenous administration of 3-5 mg/kg; (n=3)2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305748Displacement of [3H]N-alpha-methylhistamine from human cloned histamine H3 receptor expressed in C6 cells2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID237554Volume of distribution was observed in rat after intravenous administration of 1-5 mg/kg2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID239988In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID302572Ratio of drug level in brain to blood in mouse at 1 mg/kg, ip2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID86612Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from cloned human histamine H3 receptor expressed in C6 cells2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
ISSN: 0960-894X		A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID611518Displacement of [3H]NAMH from rat histamine H3 receptor expressed in CHO cells2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID692497Oral bioavailability in monkey at 1 mg/kg2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
ISSN: 1520-4804		Histamine H3 receptor as a drug discovery target.
AID611517Displacement of [3H]NAMH from human histamine H3 receptor expressed in CHO cells2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID302560Displacement of [3H]-N-alpha methyl histamine from human H3 receptor expressed in C6 cells2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302574Ratio of drug level in brain to blood in rat at 1 mg/kg, iv2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID239591In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID780100Awakening activity in rat assessed as increased wakefulness at 10 mg/kg, po after 3 to 4 hrs2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
ISSN: 1464-3405		Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
AID89863Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from histamine H3 receptor of rat cortical membranes2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
ISSN: 0960-894X		A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID237553Volume of distribution was observed in dog after intravenous administration of 1-5 mg/kg2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305753Clearance in rat brain at 1 mg/kg, iv2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID305750Half life in rat at 1 mg/kg, iv2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID236516Clearance was observed in dog after intravenous administration of 1-5 mg/kg2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID599203Displacement of [3H]N-alpha-methylhistamine from human histamine H3 receptor expressed in SK-N-MC cells2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
ISSN: 1768-3254		Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists.
AID302563Antagonist activity at human histamine H3 receptor expressed in HEK239 cells assessed as inhibition of RAMH-stimulated [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID244036Inhibition of CYP1A2 at 20 uM assessed by effect on rate of oxidation of phenacetin O-deethylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID253632Area under plasma concentration curve of the compound upon i.v. dose of 1 mg/kg in rats2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID599205Antagonist activity at human histamine H3 receptor expressed in SK-N-MC cells assessed as inhibition of forskolin stimulated cAMP accumulation after 6 hrs2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
ISSN: 1768-3254		Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists.
AID611522Bioavailability in fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID305754Cmax in rat at 1 mg/kg, po2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID246006Lowest dose to induce CNS side effects was assessed in a general behavioral screen in rats2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244034Inhibition of CYP3A4 at 2 uM assessed by effect on rate of oxidation of terfenadine hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244057Inhibition of CYP2D6 at 20 uM assessed by effect on rate of oxidation of dextromethorphan O-demethylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID692495Oral bioavailability in rat at 1 mg/kg2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
ISSN: 1520-4804		Histamine H3 receptor as a drug discovery target.
AID237263Half life was observed in dog after intravenous administration of 3-5 mg/kg; (n=3)2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305749Displacement of [3H]N-alpha-methylhistamine from histamine H3 receptor in rat cortical membranes2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID239987In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID236099Bioavailability in dog (dose 1-5 mg/kg i.v.)2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305757Oral bioavailability in rat at 1 mg/kg2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID302578Protein binding in rat plasma2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID305756AUC (0 to infinity) in rat at 1 mg/kg, po2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID616657Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
ISSN: 1464-3405		Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
AID239893Tested for its ability to block human histamine H3 receptor activation by the agonist R-alpha-methyl histamine in a [Ca2+] flux assay2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID302564Antagonist activity at rat histamine H3 receptor expressed in HEK239 cells assessed as inhibition of RAMH-stimulated [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID237820Concentration in brain of rats after 1 hr of intravenous administration2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244029Inhibition of CYP2A6 at 2 uM, assessed by effect on rate of oxidation of coumarin 7-hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID692496Oral bioavailability in dog at 1 mg/kg2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
ISSN: 1520-4804		Histamine H3 receptor as a drug discovery target.
AID246008Tested for their ability to enhance learning in the rat pups using inhibitory avoidance acquisition model2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305752AUC (0 to infinity) in rat at 1 mg/kg, iv2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID421582Displacement of [3H]N-alpha methyl histamine from human cloned histamine H3 receptor expressed in C6 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
ISSN: 1520-4804		Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
AID244037Inhibition of CYP2C9 at 20 uM assessed by its effect on rate of oxidation of Tolbutamide hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID421583Displacement of [3H]N-alpha methyl histamine from rat cortical membrane histamine H3 receptor2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
ISSN: 1520-4804		Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
AID236517Clearance was observed in rat after intravenous administration of 1-5 mg/kg2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID302573Drug level in rat brain at 1 mg/kg, iv2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302567Half life in rat at 1 mg/kg, iv2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302570Oral bioavailability in rat at 1 mg/kg2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID244033Inhibition of CYP2C9 at 2 uM assessed by effect on rate of oxidation of Tolbutamide hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244032Inhibition of CYP2A6 at 20 uM assessed by effect on rate of oxidation of coumarin 7-hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID611525Ratio of drug uptake in brain to plasma of fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID89566Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from histamine H3 receptor of rat cortical membranes2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
ISSN: 0960-894X		A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID305758Ratio of drug level in brain to plasma in rat at 5 mg/kg, iv2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID302577Protein binding in monkey plasma2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID237555Volume of distribution was observed in monkey after intravenous administration of 1-5 mg/kg2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305755Half life in rat at 1 mg/kg, po2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID302571Drug level in mouse brain at 1 mg/kg, ip2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302566Agonist activity at rat histamine H3 receptor expressed in HEK239 cells assessed as reduction of basal [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID692493Binding affinity to rat cortical histamine H3 receptor2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
ISSN: 1520-4804		Histamine H3 receptor as a drug discovery target.
AID244047Inhibition of CYP2E1 at 20 uM assessed by effect on rate of oxidation of chlorzoxazone 6-hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID611520Terminal half life in fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID302561Displacement of [3H]-N-alpha methyl histamine from rat H3 receptor expressed in C6 cells2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID86462Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from cloned human histamine H3 receptor expressed in C6 cells2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
ISSN: 0960-894X		A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID244052Inhibition of CYP2C19 at 2 uM assessed by effect on rate of oxidation of S-mephenytoin 4'-hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID253550Oral bioavailability in rat (dose 1 mg/kg)2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID254441In vitro binding affinity for human histamine H3 receptor using [3H]N-alpha-methylhistamine2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID780098Awakening activity in rat assessed as decrease of theta rhythm at 10 mg/kg, po after 3 to 4 hrs2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
ISSN: 1464-3405		Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
AID244056Inhibition of CYP2C19 at 20 uM assessed by effect on rate of oxidation of S-mephenytoin 4'-hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244031Inhibition of CYP1A2 at 2 uM assessed by effect on rate of oxidation of phenacetin O-deethylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID236100Oral bioavailability in rat (dose 1-5 mg/kg i.v.)2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID246007Tested for their ability to enhance memory in the adult rats using social recognition memory test2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244053Inhibition of CYP2D6 at 2 uM assessed by effect on rate of oxidation of dextromethorphan O-demethylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID236104Oral bioavailability in monkey (dose 1-5 mg/kg i.v.)2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244044Inhibition of CYP2E1 at 2 uM assessed by effect on rate of oxidation of chlorzoxazone 6-hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID692494Binding affinity to human histamine H3 receptor2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
ISSN: 1520-4804		Histamine H3 receptor as a drug discovery target.
AID253709Maximum plasma concentration upon p.o. dose of 1 mg/kg in rats2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID611521Systemic clearance in fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID302565Agonist activity at human histamine H3 receptor expressed in HEK239 cells assessed as reduction of basal [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302576Protein binding in human plasma2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID253809Terminal half life upon i.v. dose of 1 mg/kg in rats2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID254439In vitro binding affinity for rat histamine H3 receptor using [3H]N-alpha-methylhistamine2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID244038Inhibition of CYP3A4 at 20 uM assessed by effect on rate of oxidation of terfenadine hydroxylation upon incubation with human liver microsomes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305751Volume of distribution in rat at terminal phase at 1 mg/kg, iv2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X		4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID239562In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
ISSN: 0022-2623		4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID253810Terminal half life upon p.o. dose of 1 mg/kg in rats2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID483430Displacement of [3H]N-alpha-methylhistamine from rat cloned histamine H3 receptor2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
ISSN: 1464-3405		In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID302568Volume of distribution in rat at 1 mg/kg, iv2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
ISSN: 0022-2623		Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID375418Binding affinity to histamine H3 receptor2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
ISSN: 1520-4804		5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.
AID253576Plasma clearance upon i.v. dose of 1 mg/kg in rats2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
ISSN: 0022-2623		Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID483429Displacement of [3H]N-alpha-methylhistamine from human cloned histamine H3 receptor2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
ISSN: 1464-3405		In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID483432Selectivity ratio of Ki for human cloned histamine H3 receptor over Ki for human ERG2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
ISSN: 1464-3405		In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID1346037Human H1 receptor (Histamine receptors)2005The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1
ISSN: 0022-3565		Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
AID1346017Rat H3 receptor (Histamine receptors)2005The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1
ISSN: 0022-3565		Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
AID1346095Human H2 receptor (Histamine receptors)2005The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1
ISSN: 0022-3565		Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
AID1346107Human H3 receptor (Histamine receptors)2005The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1
ISSN: 0022-3565		Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (48.48)29.6817
2010's15 (45.45)24.3611
2020's2 (6.06)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (97.06%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
betahistine
1
aminoalkylpyridine;
secondary amino compound		H1-receptor agonist;
vasodilator agent		2009200915.0low000100
imetit
1
imidazoles;
imidothiocarbamic ester		H3-receptor agonist;
H4-receptor agonist		2011201113.0low000010
alpha-methylhistamine
1
aralkylamino compound;
imidazoles		H3-receptor agonist2009200915.0low000100
interferon-gamma
1
2009200915.0medium000100
conessine
1
steroid alkaloid;
tertiary amino compound		antibacterial agent;
antimalarial;
H3-receptor antagonist;
plant metabolite		2009200915.0low000100
jnj-5207852
5
2007201115.4high000410
4-(1h-imidazol-4-ylmethyl)piperidine
1
piperidines2011201113.0low000010
thioperamide
4
primary aliphatic amine2005201314.5low000220
ciproxifan
3
aromatic ketone2005201315.7low000210
gt 2331
1
2011201113.0medium000010
nnc 38-1049
2
2009201114.0high000110
dibutyl phthalate
4
2008201313.8medium000220
a 304121
2
2005201116.0high000110
jnj 10181457
1
2009200915.0medium000100
pitolisant
3
organochlorine compound2008200915.3low000300
a 317920
2
2005201116.0high000110
mk-0249
2
2011201113.0medium000020
pf 03654746
1
2011201113.0high000010
gsk 1004723
1
2011201113.0medium000010
cep 26401
2
pyridazines;
ring assembly		2011201113.0high000020
clozapine
1
benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic		2011201113.0low000010
olanzapine
1
benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor		2011201113.0low000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
histamine
3
aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter		2005201612.7low000120
valproic acid
1
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		2014201410.0low000010
donepezil
1
aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent		201620168.0low000010
haloperidol
2
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist		2005201016.5low000200
alpha-methylhistamine
1
aralkylamino compound;
imidazoles		animal metabolite;
H3-receptor agonist		2008200816.0low000100
ketoconazole
1
dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine		2005200519.0low000100
risperidone
1
1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist		2005200519.0low000100
apomorphine
1
aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug		2010201014.0low000100
phencyclidine
1
benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug		2010201014.0low000100
kainic acid
1
dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist		2014201410.0low000010
methamphetamine
2
amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic		2005201016.5low000200
nicotine
2
3-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic		2011201212.5low000020
benzofurans
14
2005201614.8medium000950
thioperamide
1
primary aliphatic amine2005200519.0low000100
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
1
benzenes;
thiadiazolidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent		2014201410.0low000010
dizocilpine maleate
1
maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		2010201014.0low000100
ciproxifan
2
aromatic ketone2005201016.5low000200
pitolisant
1
organochlorine compound2010201014.0low000100
piperidines
3
2005201613.7low000210
guanosine 5'-o-(3-thiotriphosphate)
2
nucleoside triphosphate analogue2005200817.5low000200
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Absence Seizure0
1
2014201410.0low000010
Academic Disorder, Developmental0
1
2010201014.0low000100
Advanced Sleep Phase Syndrome0
1
2013201311.0low000010
Age-Related Memory Disorders0
1
2010201014.0low000100
Aging0
1
2005200519.0low000100
Alcohol Drinking0
1
2010201014.0low000100
Cataleptic Attacks0
1
2005200519.0low000100
Cognition Disorders0
1
2005200519.0low000100
Congenital Zika Syndrome0
1
202020204.0low000010
Degenerative Diseases, Central Nervous System0
1
2014201410.0low000010
Delayed Effects, Prenatal Exposure0
2
2010201014.0low000200
Dementia Praecox0
3
2005200519.0low000300
Disease Models, Animal0
2
201020209.0low000110
Hyperactivity, Motor0
2
2005201116.0low000110
Learning Disabilities0
1
2010201014.0low000100
Memory Disorders0
1
2010201014.0low000100
Muscle Contraction0
1
2005200519.0low000100
Neurodegenerative Diseases0
1
2014201410.0low000010
Obesity0
1
2009200915.0low000100
Pregnancy0
2
2010201014.0low000200
Schizophrenia0
3
2005200519.0low000300
Seizures0
1
2014201410.0low000010
Sleep Disorders, Circadian Rhythm0
1
2013201311.0low000010
Zika Virus Infection0
1
202020204.0low000010

Safety/Toxicity (1)

ArticleYear
Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice.
Brain research, , Sep-18, Volume: 1581		2014

Bioavailability (4)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019
Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 23, Issue:22		2013
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15		2009
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
The Journal of pharmacology and experimental therapeutics, , Volume: 313, Issue:1		2005

Dosage (1)

ArticleYear
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 re
The Journal of pharmacology and experimental therapeutics, , Volume: 313, Issue:1		2005

Interactions (1)

ArticleYear
Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Brain research, , May-31, Volume: 1045, Issue:1-2		2005